Literature DB >> 2154995

Thiol oxidation and inhibition of Ca-ATPase by adriamycin in rabbit heart microsomes.

G Vile1, C Winterbourn.   

Abstract

Incubation of rabbit heart microsomes with Adriamycin and NADPH resulted in the oxidation of approximately 25% of protein thiols and 66% inhibition of Ca-ATPase activity. Thiol oxidation and Ca-ATPase inactivation were iron-dependent and could be catalysed by ferritin. Removal of contaminating catalase revealed that both processes required H2O2 which could be supplied by O2 under aerobic conditions. However, O2- was not involved. Butylated hydroxytoluene (BHT), alpha-tocopherol and beta-carotene inhibited lipid peroxidation of microsomes, but did not inhibit thiol oxidation or the inactivation of Ca-ATPase. Likewise, the hydroxyl radical scavengers benzoate, formate and mannitol were not inhibitory. Glutathione (GSH), however, prevented inactivation of Ca-ATPase. It is concluded that Adriamycin-enhanced redox reactions involving iron and H2O2 are responsible for oxidizing microsomal thiol groups and inhibition of Ca-ATPase. Disruption of Ca transport within the myocyte by this process could contribute to the cardiotoxicity of Adriamycin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2154995     DOI: 10.1016/0006-2952(90)90157-g

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  3 in total

Review 1.  Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics.

Authors:  James H Doroshow
Journal:  Curr Pharm Biotechnol       Date:  2012-08       Impact factor: 2.837

2.  Fibronectin turnover in human mesangial cell cultures as affected by adriamycin.

Authors:  M Soose; S Wenzel; H Stolte
Journal:  Cell Biol Toxicol       Date:  1993 Apr-Jun       Impact factor: 6.691

3.  Mechanisms of Anthracycline-Enhanced Reactive Oxygen Metabolism in Tumor Cells.

Authors:  James H Doroshow
Journal:  Oxid Med Cell Longev       Date:  2019-12-03       Impact factor: 6.543

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.